Company: Open Orphan (ORPH)
Presenter: Cathal Friel, Executive Chairman
Date: Monday 11th May 2020
Time: 5pm start – 6pm finish
Open Orphan is a newly created niche CRO pharmaceutical services company which is the world leader in testing vaccines & antivirals through human challenge studies. Open Orphan is actively involved in the fight against COVID-19 and is developing the world’s first coronavirus challenge study model.
In June 2019 Open Orphan acquired AIM-listed Venn Life Sciences plc in a reverse take-over and in January 2020 completed a merger with hVIVO plc. hVIVO has Europe’s only 24-bedroom quarantine clinic with onsite virology lab and has recently commenced testing on a potential antiviral treatment for COVID-19
Open Orphan (ORPH) is quoted on both the AIM and Euronext Growth market
Registration is open to members of ShareSoc. You need to be logged in to this website as a member to register. If you are not a member and would like to register, click here to join ShareSoc first. If you are a member and are not able to login, you will find instructions here.
If you are logged in, please click the button below to proceed to registration.Register for Webinar